Boston Pharmaceuticals Inc.

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

Following GSK’s $1.2bn acquisition of privately held Boston Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) candidate efimosfermin on 14 May, the industry is wondering what re

In the highly competitive race to follow Madrigal to market in metabolic dysfunction-associated steatohepatitis (MASH), perhaps the two most closely watched drug classes are the GLP-1 agonists, which

When Akero Therapeutics failed to meet the 36-week primary endpoint in its Phase IIb SYMMETRY study of efruxifermin in metabolic dysfunction-associated steatohepatitis (MASH) in October 2023, the comp